Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

May 14, 2025

Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 7, 2025

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Apr 1, 2025

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

Mar 26, 2025

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

Mar 24, 2025

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Mar 19, 2025

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Mar 12, 2025

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 5, 2025

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 4, 2025

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

Jan 23, 2025

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

1
2
3
4
5
6
7
8
arrow_forward

rss_feed News RSS